Amneal Pharmaceuticals (AMRX) Restructuring Costs (2017 - 2026)

Amneal Pharmaceuticals' Restructuring Costs history runs 10 years deep, the most recent figure standing at $5.2 million for Q1 2026.

• On a quarterly basis, Restructuring Costs rose 802.45% year-over-year to $5.2 million in Q1 2026; TTM through Mar 2026 was $8.8 million, a 503.71% increase from a year earlier, with the FY2025 full-year figure at $4.2 million, up 78.68% from the prior year.
• Restructuring Costs climbed to $5.2 million in Q1 2026 per AMRX's latest filing, from $2.5 million in the prior quarter.
• Across five years, Restructuring Costs topped out at $5.2 million in Q1 2026 and bottomed at -$612000.0 in Q4 2022.
• The 5-year median for Restructuring Costs is $540500.0 (2023), against an average of $885312.5.
• Across the five-year window, Restructuring Costs sank 108.37% in 2022 and soared 802.45% in 2026, its largest moves.
• Year by year, Restructuring Costs stood at -$612000.0 in 2022, then soared by 118.63% to $114000.0 in 2023, then jumped by 332.46% to $493000.0 in 2024, then jumped by 401.01% to $2.5 million in 2025, then jumped by 108.62% to $5.2 million in 2026.
• Per Business Quant, the three latest AMRX Restructuring Costs figures stand at $5.2 million (Q1 2026), $2.5 million (Q4 2025), and $143000.0 (Q3 2025).